USPTO serial 99545602
OPTEIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MORENO, PAUL A
- Law office
- TMEG LAW OFFICE 103
What this means
Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.
Need help with OPTEIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Makiko Coffland
Makiko Coffland Christensen O'Connor Johnson Kindness1201 Third Avenue, Suite 3600Seattle, WA 98101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in the pharmaceutical industry; Biological preparations for use in industry | ACTIVE | — |
| 003 | Cosmetic preparations; non-medicated skincare preparations | ACTIVE | — |
| 005 | Pharmaceutical preparations for use in the diagnosis, treatment, or prevention of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty related diseases or disorders, gynecological disorders, fertility, acromegaly and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases and disorders, muscle disorders, bone disorders, skeletal disorders, peripheral nervous system disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain; pharmaceutical preparations for aesthetic and therapeutic use, including for the diagnosis, treatment, or prevention of glabellar lines, forehead lines, lateral canthal lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations for skin care | ACTIVE | — |
| 009 | Downloadable computer software for scientific analysis within the medical field; computer hardware; downloadable data processing computer software; Computer hardware and recorded software systems for data processing | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, analysis, testing, and diagnosis for the treatment or prevention of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty related diseases or disorders, gynecological disorders, fertility, acromegaly and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases and disorders, muscle disorders, bone disorders, skeletal disorders, peripheral nervous system disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, forehead lines, lateral canthal lines, facial wrinkles, asymmetries and defects and conditions of the human skin, skin care; scientific research and development; medical research; design and development of computer hardware and software; product design and development in the fields of pharmaceuticals, cosmetics, and medical devices; pharmaceutical products development; testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others; Medical research laboratory services; providing online, non-downloadable software for scientific analysis within the medical field; consultancy and information services relating to the scientific formulation of pharmaceutical products; pharmaceutical research services | ACTIVE | — |
| 044 | Pharmaceutical compounding services; dispensing of pharmaceuticals; medical services; healthcare services; providing medical information; consultancy and information services relating to pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by IPSEN BIOPHARM LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named OPTEIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 3, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 3, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 3, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 15, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 17, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 16, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 12, 2025 | NWAP | NEW APPLICATION ENTERED | — |